No description available.

Pentameriska ligandstyrda jonkanaler (pLGICs) är avgörande för omvandlingen av kemisk till elektrisk signalöverföring i djurs nervsystem. Dysfunktion i dessa kanaler har visat sig vara kopplad till flera sjukdomar inklusive epilepsi, schizofreni, Alzheimers och autism, vilket gör dem till en måltavla för en mängd olika läkemedel. Att studera eukaryota kanaler är dock mycket utmanande, så upptäckten av prokaryota homologer, som är mycket lättare att studera, har därmed bidragit mycket till förståelsen för struktur och funktion hos proteiner i denna familj. I detta projekt producerades och renades en prokaryotisk pLGIC kallad DeCLIC från Escherichia coli. Strukturell bestämning av kanalen genomfördes med användning av kryo-elektronmikroskopi vid lågt pH och i närvaro av kalcium. En elektrontäthet med 3.4 Å upplösning uppnåddes och jämfördes med tidigare bestämda strukturer vid olika förhållanden i ett försök att bestämma hur proteinets struktur moduleras av kalcium och pH. Resultaten visar flera skillnader i kanalens konformation i närvaro och frånvaro av kalcium såväl som vid olika pH-värden. Dessutom antyder analys av den bestämda elektrontätheten ett möjligt intermediärt tillstånd vid lågt pH i närvaro av kalcium. / Pentameric ligand-gated ion channels (pLGICs) are crucial for the conversion of chemical to electrical signaling in the nervous system of mammals. Dysfunction in these channels has been found to be connected to several diseases including epilepsy, schizophrenia, Alzheimer’s, and autism, making them the target of a wide variety of therapeutic agents. However, studying eukaryotic channels is challenging so the discovery of prokaryotic homologs that are much easier to study has thus greatly helped in the understanding of the structure and function in this family of proteins. In this project, a prokaryotic pLGIC called DeCLIC was produced and purified from Escherichia coli. Structural determination of the channel was pursued using cryo-electron microscopy at a low pH and in the presence of calcium. An electron density at 3.4 Å resolution was achieved and compared to previously determined structures at different conditions in an attempt to determine the structural modulation of calcium and pH. Results show multiple differences in channel conformation in the presence and absence of calcium as well as in different pH conditions. Furthermore, analysis of the determined electron density suggests a possible intermediate state at low pH in the presence of calcium.

No description available.

No description available.

<p>Coronaviruses (CoVs) are single-stranded, positive-sense RNA viruses in the Coronaviridae family. Within this family are four different genera, Alpha-, Beta-, Gamma-, and Deltacoronaviruses with human-infecting CoVs spanning the Alpha- and Beta-CoV genera. Most notably, Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1) and SARS-CoV-2 are Betacoronaviruses that spread worldwide in their outbreaks from 2002-2003 (SARS-CoV-1) and 2019-2020 (SARS-CoV-2). Human-infecting Alphacoronaviruses, NL63-CoV and 229E-CoV, have caused milder infections involving respiratory disease, gastroenteritis, and in more severe cases, death. Despite milder disease, Alphacoronaviruses are the cause of 15-30% of severe upper and lower respiratory tract infections each year. There have been recent efforts in the development of potent, small-molecule inhibitors to treat SARS-CoV-2 infection but there is an ongoing need to develop new and effective anti-coronavirus therapeutics to treat other human-infecting CoVs circulating society. Coronaviruses encode two essential proteases, the papain-like protease (PLP) and the 3C-like protease. PLPs are cysteine proteases located in non-structural protein 3 (nsp3). PLPs processes the viral polyprotein, releasing the first three nonstructural proteins encoded in the virus, and also are involved in evading the innate immune response through deubiquitinating (DUB) and deISGylating activity. </p> <p><br></p> <p>This study compares the substrate specificity and catalytic function of multiple human-infecting PLPs from both Alpha- and Beta-CoVs including NL63-CoV PLP2, 229E-CoV PLP2, Canine-CoV PLP2, FIPV-CoV PLP2, PEDV-CoV PLP2, SARS-CoV-1 PLpro, and SARS-CoV-2 PLpro. Interestingly, Alphacoronavirus PLP2s have a >400-fold greater catalytic efficiency for ubiquitin compared to Betacoronaviruses PLpro. This work also identifies a non-covalent scaffold of inhibitors that has pan-CoV inhibition; however, the IC50 values are >30-fold higher for NL63-CoV PLP2 than for SARS-CoV-1 PLpro. The X-ray structures of NL63 PLP2 and 229E PLP2 were determined to 2.1 Å and 1.8 Å, respectively, and provide structural information about the substrate and inhibitor binding region that could be the result in the differences in Alpha- and Betacoronavirus PLP function. Since PLP does not function as a single-domain in vivo, it is critical to understand the function of PLP when tethered to other domains of nsp3. This study also investigates nine different constructs of SARS-CoV-2 nsp3 with increasing domains, ranging from the single PLpro domain to Ubl1-Ydomain ΔTM1-TM2. Interestingly, the longer constructs of SARS-CoV-2 nsp3 show less catalytic efficiency for Ub-AMC and greater affinity for ISG15-AMC, with 8-fold lower Km values compared to PLpro alone. Lastly, each SARS-CoV-2 nsp3 construct was inhibited by a known PLpro inhibitor, GRL-0617, with reported IC50 values ranging from 0.91 μM to 1.9 μM. These data show that GRL-0617 still remains a lead compound to be optimized for cellular potency. </p> <p><br></p> <p>Overall, this dissertation advances the understanding of the kinetic and structural differences between Alphacoronavirus PLP2 and Betacoronavirus PLpro enzymes in the efforts of developing a pan-CoV inhibitor. Additionally, these data provide initial kinetic and biophysical characterization of PLpro within the larger context of nsp3 to elucidate the function of PLpro in its most native context during coronaviral infection.</p>

Tuberculosis (TB) is an infectious and fatal disease that ranks as the second leading killer worldwide. It is caused by Mycobacterium tuberculosis (Mtb) which is an obligate intracellular parasite that colonizes the alveolar macrophages of the immune system. The major health concern associated with TB is its co-infection with HIV and the development of strains with multi-drug resistance. The elimination of TB has been hindered due to the lack of understanding of the survival strategies used by this pathogen. Thus, research towards discovering new effective antibacterial drugs is necessary and a group of Mtb kinase enzymes were targeted in this study because these enzymes are crucial for metabolism, pathogenesis and, hence, the survival of Mtb. Kinases are a group of structurally distinct and diverse proteins that catalyze the transfer of the phosphate group from high energy donor molecules such as ATP (or GTP) to a substrate. The phosphorylation of proteins modifies the activity of specific proteins which is subsequently used to control complex cellular processes within Mtb. The starting point of this research targeted eight specific Mtb kinases namely; Nucleoside diphosphokinase, Homoserine kinase, Acetate kinase, Glycerol kinase, Thiamine monophosphate kinase, Ribokinase, Aspartokinase and Shikimate kinase. The aim of this project was to subclone the gene sequences for these eight recombinant Mtb kinases and express them in Escherichia coli, to purify the proteins and determine their activity. In the effort to find new lead compounds, the final stage of this study focused on the basic screening of the TB kinases against an extract prepared from Pelargonium sidoides, a medicinal plant, to identify any inhibitory effects. Although this traditional medicinal plant has been broadly researched and extensively used to treat TB, there is still a lack of understanding of this plant’s scientific curative effect. Various molecular and biochemical methods were used to achieve the aims of this project. The putative gene sequence was obtained from the annotated genome of H37Rv, deposited at NCBI as NC_000962.2. The genes encoding the kinases were successfully PCR-amplified from genomic DNA, cloned into an expression vector in-frame with a C- or N-terminal 6-histidine-tag and expressed in E. coli BL21 (DE3). The purification of the protein was complex, but various different methods and techniques were explored to obtain sufficient amounts of protein. The functional characterization of the kinases involved an HPLC enzyme assay that showed that the recombinant kinases were active. These enzymes were then screened against the potential inhibitory compounds in P. sidoides using enzyme assays to generate dose-response curves. This allowed an effective comparison not only of the Mtb kinases’ activity under normal conditions but also the kinases’ activity in the presence of a potential inhibitor. Overall, the inhibition of the enzymes required the presence of higher concentrations of the P. sidoides extract. However, the SK enzyme results presented a significantly higher inhibition and the lowest IC50 value, in comparison to the other kinases, which makes this kinase an attractive potential drug target against TB. In summation, cloning and purification of SK was successful, resulting in a concentration of 2030 μg/ml of purified enzyme and its activity analysis demonstrated enzyme functionality. This activity was reduced to zero in the presence of 1 x 102 mg/ml dilution of P. sidoides plant extract. This research conducted has extended the quality of information available in this field of study. These interesting results, proposing and identifying SK as a suitable potential target can be a starting point to significantly contribute and progress in this field of research, with the eventual goal of developing a drug to combat this fatal disease. / Life Sciences / M. Sc. (Life Sciences)

L’athérosclérose est une maladie vasculaire inflammatoire chronique qui se développe progressivement au cours de la vie. Les mécanismes impliqués sont complexes et la recherche de nouveaux candidats impliqués dans l'athérogénèse est toujours d'actualité. L’Angiopoietine-like 2 (Angptl2) est une protéine relativement peu connue, aux propriétés pro-angiogéniques et pro-inflammatoires, qui appartient par homologie à la grande famille des angiopoietines, mais dont le récepteur n'est pas encore clairement identifié. Les situations pathologiques dans lesquelles l’Angptl2 jouerait un rôle crucial sont diverses, mais sa contribution moléculaire dans le développement de l’athérosclérose est inconnue. Par differential display, nous avons initialement identifié l'Angptl2 comme étant surexprimée dans des cellules endothéliales sénescentes, isolées et cultivées à partir d'artères mammaires internes de patients athérosclérotiques ayant subi un pontage coronarien. Cette découverte a été la à base de mon projet, et mes objectifs ont été 1) de déterminer l'implication de l’Angptl2 vasculaire en présence de facteurs de risques tels que le tabagisme et la dyslipidémie, 2) de produire et de purifier une protéine recombinante fonctionnelle de l’Angptl2 afin d'identifier in vitro de nouvelles propriétés cellulaires de l'Angptl2 et 3) d'étudier in vivo le potentiel pro-athérogénique de l'Angptl2 recombinante dans un modèle murin de dyslipidémie sévère. Nous avons montré que l’Angptl2 est sécrétée préférentiellement dans des conditions pro-oxydantes et pro-inflammatoires, avec une augmentation de son expression endothéliale de l’ordre de 6 fois chez des patients coronariens fumeurs atteints de maladie pulmonaire obstructive chronique. Suite à ces résultats, nous avons émis l’hypothèse que l’Angptl2, en plus de ses fonctions pro-inflammatoires connues, possède des propriétés pro-oxydantes. Nous avons démontré que l’Angptl2 recombinante stimule en effet la production de radicaux libres dans des HUVEC en culture, via l’inhibition partielle de la voie cytoprotectrice antioxydante Nrf2/HO-1 et potentiellement via l'activation de kinase intracellulaire de type p38. A l'aide de souris dyslipidémiques LDLr-/-; hApoB-100+/+, nous avons démontré que le niveau d’Angptl2 plasmatique, vasculaire et dans les plaques athéromateuses, augmente parallèlement avec le développement de l’athérosclérose. De plus, une stimulation avec l’Angptl2 recombinante engendre chez ces souris une réponse inflammatoire évaluée par l’expression endothéliale de cytokines et de molécules d'adhésion et par l’infiltration de leucocytes sur l’endothélium vasculaire. Finalement, l’administration intraveineuse de la protéine recombinante d’Angptl2 pendant quatre semaines à des souris LDLr-/-; hApoB-100+/+ augmente de 10 fois l'expansion de la plaque athérosclérotique et double leur taux de cholestérol circulant. Nous avons aussi montré que chez des patients athérosclérotiques, l'Angptl2 plasmatique est 6 fois plus élevée que chez des sujets sains du même âge. Nos études semblent donc définir l’Angptl2 comme un facteur contribuant directement au développement de l'athérosclérose en favorisant la sénescence, l’inflammation et l’oxydation des cellules endothéliales. Ces propriétés pourraient globalement définir l'Angptl2, non seulement comme un nouveau biomarqueur circulant de l’athérosclérose, mais également comme l'un de ses promoteurs. / Atherosclerosis is a chronic vascular inflammatory disease that develops gradually during life. While the control mechanisms of this disease are complex and variable, research continues to identify new protein candidates involved in atherogenesis. Angiopoietin-like2 (Angptl2) is a relatively unknown protein, recently shown to display angiogenic and pro-inflammatory properties. Based upon structural homology, Angptl2 is a member of the angiopoietin family; however, the Angptl2 receptor has not yet been clearly identified. The reported pathological situations in which Angptl2 may play a crucial role are multiple, but its molecular contribution in the development of atherosclerosis remains unknown. By differential display, we initially identified Angptl2 as being overexpressed in senescent endothelial cells, isolated and cultivated from internal mammary arteries of atherosclerotic patients undergoing coronary bypass. This observation was at the basis of my project. My specific objectives were 1) to determine the abundance of vascular Angptl2 in the presence of risk factors such as smoking and dyslipidemia, 2) to produce and purify a functional recombinant human Angptl2 protein in order to examine its effects on cellular function in vitro, and 3) to study the pro-atherogenic potential of Angptl2 in vivo using a mouse model of severe dyslipidemia. We showed that Angptl2 is preferentially secreted under pro-oxidant and pro-inflammatory conditions, with a 6-fold increase in endothelial Angptl2 expression in smoker coronary patients with chronic obstructive pulmonary disease. Based on these results, we hypothesized that, in addition to its known pro-inflammatory functions, Angptl2 has pro-oxidant properties. Accordingly, we demonstrated that recombinant Angptl2 stimulates the production of free radicals by HUVEC, an action exerted, at least in part, by the inhibition of the cytoprotective antioxidant pathway, Nrf2/HO-1, and potentially via the activation of the intracellular p38 MAPK pathway. In dyslipidemic LDLr-/-; hApoB-100+/+ mice, we showed that the levels of endogenous Angptl2 in plasma, vascular tissue and atherosclerotic lesions increase in parallel with the development of atherosclerosis. In addition, stimulation with recombinant Angptl2 induces an inflammatory response, as assessed by the expression of cytokines and adhesion molecules and by infiltration of leukocytes into the vascular endothelium. Furthermore, intravenous infusion of purified recombinant Angptl2 for four weeks promoted a 10-fold increase in the formation of atherosclerotic plaques in LDLr-/-; hApoB-100+/+ mice and doubled their circulating cholesterol levels. Finally, we also demonstrated that plasma Angptl2 is 6-fold higher in atherosclerotic patients than in age-matched healthy subjects. These studies therefore strongly suggest that Angptl2 could directly contribute to the development of atherosclerosis by promoting senescence, inflammation and oxidation in endothelial cells. Such properties indicate that Angptl2 may be both a new biomarker of atherosclerosis, as well as one of its contributors.

L’athérosclérose est une maladie vasculaire inflammatoire chronique qui se développe progressivement au cours de la vie. Les mécanismes impliqués sont complexes et la recherche de nouveaux candidats impliqués dans l'athérogénèse est toujours d'actualité. L’Angiopoietine-like 2 (Angptl2) est une protéine relativement peu connue, aux propriétés pro-angiogéniques et pro-inflammatoires, qui appartient par homologie à la grande famille des angiopoietines, mais dont le récepteur n'est pas encore clairement identifié. Les situations pathologiques dans lesquelles l’Angptl2 jouerait un rôle crucial sont diverses, mais sa contribution moléculaire dans le développement de l’athérosclérose est inconnue. Par differential display, nous avons initialement identifié l'Angptl2 comme étant surexprimée dans des cellules endothéliales sénescentes, isolées et cultivées à partir d'artères mammaires internes de patients athérosclérotiques ayant subi un pontage coronarien. Cette découverte a été la à base de mon projet, et mes objectifs ont été 1) de déterminer l'implication de l’Angptl2 vasculaire en présence de facteurs de risques tels que le tabagisme et la dyslipidémie, 2) de produire et de purifier une protéine recombinante fonctionnelle de l’Angptl2 afin d'identifier in vitro de nouvelles propriétés cellulaires de l'Angptl2 et 3) d'étudier in vivo le potentiel pro-athérogénique de l'Angptl2 recombinante dans un modèle murin de dyslipidémie sévère. Nous avons montré que l’Angptl2 est sécrétée préférentiellement dans des conditions pro-oxydantes et pro-inflammatoires, avec une augmentation de son expression endothéliale de l’ordre de 6 fois chez des patients coronariens fumeurs atteints de maladie pulmonaire obstructive chronique. Suite à ces résultats, nous avons émis l’hypothèse que l’Angptl2, en plus de ses fonctions pro-inflammatoires connues, possède des propriétés pro-oxydantes. Nous avons démontré que l’Angptl2 recombinante stimule en effet la production de radicaux libres dans des HUVEC en culture, via l’inhibition partielle de la voie cytoprotectrice antioxydante Nrf2/HO-1 et potentiellement via l'activation de kinase intracellulaire de type p38. A l'aide de souris dyslipidémiques LDLr-/-; hApoB-100+/+, nous avons démontré que le niveau d’Angptl2 plasmatique, vasculaire et dans les plaques athéromateuses, augmente parallèlement avec le développement de l’athérosclérose. De plus, une stimulation avec l’Angptl2 recombinante engendre chez ces souris une réponse inflammatoire évaluée par l’expression endothéliale de cytokines et de molécules d'adhésion et par l’infiltration de leucocytes sur l’endothélium vasculaire. Finalement, l’administration intraveineuse de la protéine recombinante d’Angptl2 pendant quatre semaines à des souris LDLr-/-; hApoB-100+/+ augmente de 10 fois l'expansion de la plaque athérosclérotique et double leur taux de cholestérol circulant. Nous avons aussi montré que chez des patients athérosclérotiques, l'Angptl2 plasmatique est 6 fois plus élevée que chez des sujets sains du même âge. Nos études semblent donc définir l’Angptl2 comme un facteur contribuant directement au développement de l'athérosclérose en favorisant la sénescence, l’inflammation et l’oxydation des cellules endothéliales. Ces propriétés pourraient globalement définir l'Angptl2, non seulement comme un nouveau biomarqueur circulant de l’athérosclérose, mais également comme l'un de ses promoteurs. / Atherosclerosis is a chronic vascular inflammatory disease that develops gradually during life. While the control mechanisms of this disease are complex and variable, research continues to identify new protein candidates involved in atherogenesis. Angiopoietin-like2 (Angptl2) is a relatively unknown protein, recently shown to display angiogenic and pro-inflammatory properties. Based upon structural homology, Angptl2 is a member of the angiopoietin family; however, the Angptl2 receptor has not yet been clearly identified. The reported pathological situations in which Angptl2 may play a crucial role are multiple, but its molecular contribution in the development of atherosclerosis remains unknown. By differential display, we initially identified Angptl2 as being overexpressed in senescent endothelial cells, isolated and cultivated from internal mammary arteries of atherosclerotic patients undergoing coronary bypass. This observation was at the basis of my project. My specific objectives were 1) to determine the abundance of vascular Angptl2 in the presence of risk factors such as smoking and dyslipidemia, 2) to produce and purify a functional recombinant human Angptl2 protein in order to examine its effects on cellular function in vitro, and 3) to study the pro-atherogenic potential of Angptl2 in vivo using a mouse model of severe dyslipidemia. We showed that Angptl2 is preferentially secreted under pro-oxidant and pro-inflammatory conditions, with a 6-fold increase in endothelial Angptl2 expression in smoker coronary patients with chronic obstructive pulmonary disease. Based on these results, we hypothesized that, in addition to its known pro-inflammatory functions, Angptl2 has pro-oxidant properties. Accordingly, we demonstrated that recombinant Angptl2 stimulates the production of free radicals by HUVEC, an action exerted, at least in part, by the inhibition of the cytoprotective antioxidant pathway, Nrf2/HO-1, and potentially via the activation of the intracellular p38 MAPK pathway. In dyslipidemic LDLr-/-; hApoB-100+/+ mice, we showed that the levels of endogenous Angptl2 in plasma, vascular tissue and atherosclerotic lesions increase in parallel with the development of atherosclerosis. In addition, stimulation with recombinant Angptl2 induces an inflammatory response, as assessed by the expression of cytokines and adhesion molecules and by infiltration of leukocytes into the vascular endothelium. Furthermore, intravenous infusion of purified recombinant Angptl2 for four weeks promoted a 10-fold increase in the formation of atherosclerotic plaques in LDLr-/-; hApoB-100+/+ mice and doubled their circulating cholesterol levels. Finally, we also demonstrated that plasma Angptl2 is 6-fold higher in atherosclerotic patients than in age-matched healthy subjects. These studies therefore strongly suggest that Angptl2 could directly contribute to the development of atherosclerosis by promoting senescence, inflammation and oxidation in endothelial cells. Such properties indicate that Angptl2 may be both a new biomarker of atherosclerosis, as well as one of its contributors.

Human α-N-Acetylglucosaminidase (Naglu) is a lysosomal acid hydrolase implicated in tthe rare metabolic storage disorder known as mucopolysaccharidosis type IIIB (MPS IIIB; also Sanfilippo syndrome B). Absence of this enzyme results in cytotoxic accumulation of heparan sulphate in the central nervous system, causing mental retardation and a shortened lifespan. Enzyme replacement therapy is not currently effective to treat neurological symptoms due to the inability of exogenous Naglu to access the brain. This laboratory uses a Spodoptera frugiperda (Sf9) insect cell system to express Naglu fused to a synthetic protein transduction domain with the intent to facilitate delivery of Naglu across the blood-brain barrier. The project described herein may be broken down into three main sections. Firstly, the impact of two cryptic splice sites on Naglu expression levels was analyzed in both transiently expressing Sf9 cultures and stably selected cell lines. Secondly, the effectiveness of the native Naglu secretion-signaling peptide in the Sf9 system was examined. Finally, purification of a Naglu fusion protein from suspension culture medium was performed using hydrophobic interaction chromatographic techniques. The ultimate goal of this research is to develop an efficient system for economical, large-scale production of a human recombinant Naglu fusion protein that has the potential to be successfully used for enzyme replacement therapy to treat MPS IIIB. / Graduate

Tuberculosis (TB) is an infectious and fatal disease that ranks as the second leading killer worldwide. It is caused by Mycobacterium tuberculosis (Mtb) which is an obligate intracellular parasite that colonizes the alveolar macrophages of the immune system. The major health concern associated with TB is its co-infection with HIV and the development of strains with multi-drug resistance. The elimination of TB has been hindered due to the lack of understanding of the survival strategies used by this pathogen. Thus, research towards discovering new effective antibacterial drugs is necessary and a group of Mtb kinase enzymes were targeted in this study because these enzymes are crucial for metabolism, pathogenesis and, hence, the survival of Mtb. Kinases are a group of structurally distinct and diverse proteins that catalyze the transfer of the phosphate group from high energy donor molecules such as ATP (or GTP) to a substrate. The phosphorylation of proteins modifies the activity of specific proteins which is subsequently used to control complex cellular processes within Mtb. The starting point of this research targeted eight specific Mtb kinases namely; Nucleoside diphosphokinase, Homoserine kinase, Acetate kinase, Glycerol kinase, Thiamine monophosphate kinase, Ribokinase, Aspartokinase and Shikimate kinase. The aim of this project was to subclone the gene sequences for these eight recombinant Mtb kinases and express them in Escherichia coli, to purify the proteins and determine their activity. In the effort to find new lead compounds, the final stage of this study focused on the basic screening of the TB kinases against an extract prepared from Pelargonium sidoides, a medicinal plant, to identify any inhibitory effects. Although this traditional medicinal plant has been broadly researched and extensively used to treat TB, there is still a lack of understanding of this plant’s scientific curative effect. Various molecular and biochemical methods were used to achieve the aims of this project. The putative gene sequence was obtained from the annotated genome of H37Rv, deposited at NCBI as NC_000962.2. The genes encoding the kinases were successfully PCR-amplified from genomic DNA, cloned into an expression vector in-frame with a C- or N-terminal 6-histidine-tag and expressed in E. coli BL21 (DE3). The purification of the protein was complex, but various different methods and techniques were explored to obtain sufficient amounts of protein. The functional characterization of the kinases involved an HPLC enzyme assay that showed that the recombinant kinases were active. These enzymes were then screened against the potential inhibitory compounds in P. sidoides using enzyme assays to generate dose-response curves. This allowed an effective comparison not only of the Mtb kinases’ activity under normal conditions but also the kinases’ activity in the presence of a potential inhibitor. Overall, the inhibition of the enzymes required the presence of higher concentrations of the P. sidoides extract. However, the SK enzyme results presented a significantly higher inhibition and the lowest IC50 value, in comparison to the other kinases, which makes this kinase an attractive potential drug target against TB. In summation, cloning and purification of SK was successful, resulting in a concentration of 2030 μg/ml of purified enzyme and its activity analysis demonstrated enzyme functionality. This activity was reduced to zero in the presence of 1 x 102 mg/ml dilution of P. sidoides plant extract. This research conducted has extended the quality of information available in this field of study. These interesting results, proposing and identifying SK as a suitable potential target can be a starting point to significantly contribute and progress in this field of research, with the eventual goal of developing a drug to combat this fatal disease. / Life Sciences / M. Sc. (Life Sciences)